ArticleCureus2025
Clinical Outcomes of Dupilumab-Associated Ocular Surface Disease in the Paediatric Population.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The aim of this study is to characterise dupilumab-associated ocular surface disease (DAOSD) and its management in the paediatric population. Methods Retrospective data were obtained from the electronic medical records of a tertiary Australian paediatric public hospital's Ophthalmology department for patients reviewed between 1 January 2021 and 1 December 2024. Demographic information was recorded, including gender, age when dupilumab was started, ethnicity, dupilumab indication, past medical history, and baseline serology testing. Clinical characteristics collected included presenting visual acuity (VA), ophthalmological findings, ocular treatment, time to onset and resolution of DAOSD, and final ophthalmological outcome. Cessation of dupilumab due to DAOSD was also noted. Results A total of 13 patients were identified with DAOSD. The mean time from starting dupilumab to onset of DAOSD was 24 weeks (7.3-97.9 weeks). The mean time from onset of ocular symptoms to ophthalmology review was 3.6 weeks (range 0.1-8). The mean baseline VA was logMAR 0.01 (range 0-0.3). Ophthalmological examination findings included conjunctival injection (n=9, 69%), papillary reaction (n=5, 39%), superficial punctate keratitis (n=5, 39%), limbitis (n=3, 23%), and periocular involvement (n=2, 14%). Management included lubricant eye drops (n=13, 100%), topical steroid drops (n=9, 80%), topical antihistamines/mast cell stabiliser eye drops (n=5, 39%), and systemic azithromycin (n=1, 8%). The mean final VA was logMAR 0.06 (range 0-0.3). Three (23%) patients discontinued dupilumab due to ocular or systemic side effects. Conclusions Early ophthalmological assessment and intervention can lead to positive final visual outcomes in paediatric patients experiencing DAOSD. Future studies should investigate the long-term effects of DAOSD treatment in the paediatric population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.